Paxlovid Dosing for GFR 60 mL/min/1.73 m²
For a patient with a GFR of 60 mL/min/1.73 m², you should prescribe the standard full dose of Paxlovid: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) taken together twice daily for 5 days. 1
Rationale Based on Renal Function Categories
A GFR of 60 mL/min/1.73 m² sits at the threshold between normal and moderate renal impairment. The FDA labeling clearly defines dosing adjustments based on specific eGFR cutoffs 1:
- eGFR ≥60 mL/min: Standard dose (300/100 mg twice daily)
- eGFR 30 to <60 mL/min: Reduced dose (150/100 mg twice daily)
- eGFR <30 mL/min: Modified regimen with once-daily dosing after Day 1
Since your patient has an eGFR of exactly 60 mL/min/1.73 m², they fall into the normal dosing category and do not require dose reduction.
Pharmacokinetic Justification
This dosing strategy is supported by pharmacokinetic data showing that nirmatrelvir exposure increases progressively with worsening renal function 2. In patients with moderate renal impairment (eGFR 30-59 mL/min), systemic exposure increased to 187% of normal, necessitating dose reduction. However, at eGFR ≥60 mL/min, the exposure remains within acceptable therapeutic ranges without requiring adjustment 2, 3.
The WHO guideline also supports dose reduction only when eGFR falls to 30-59 mL/min 4, aligning with the FDA recommendations.
Critical Practical Considerations
Before prescribing, you must:
- Review all current medications for drug-drug interactions, as ritonavir is a potent CYP3A4 inhibitor that can cause serious, life-threatening interactions 1, 5
- Initiate treatment within 5 days of symptom onset for maximum benefit 1
- Administer at approximately the same time each day with or without food 1
Common Pitfall to Avoid
Do not reflexively reduce the dose simply because the patient has "some degree of kidney disease." The eGFR of 60 mL/min/1.73 m² is the specific cutoff—at or above this value, full dosing is both safe and necessary to maintain adequate antiviral concentrations. Underdosing at this GFR level could compromise therapeutic efficacy without providing additional safety benefit.
Recent evidence in patients with advanced kidney dysfunction (eGFR 15-30 mL/min) demonstrates that appropriately dose-adjusted nirmatrelvir/ritonavir reduces respiratory complications without increasing cardiovascular or hepatic adverse events 6, further supporting the safety of the standard dose at higher GFR values.